Although previous studies have demonstrated that pharmacological inhibition of PDE4 can reduce inflammation in AD[9, 10, 11]; the currently available PDE4 inhibitors, such as roflumilast, are often associated with significant side effects, limiting their clinical utility.[12, 13, 14] Thus, identifying novel and more selective PDE4D‐targeted therapies represents a promising avenue for AD treatment. This evidence concerns the gene PDE4A and Alzheimer disease.